Oncology

Oncology research accounts for nearly 25% of active studies globally. Since our founding, AG Mednet has fast-deployed our solutions to support thousands of Oncology trials. Within the last four years, Judi by AG Mednet has optimized over 720 Oncology-focused studies, including over250 Phase II and 160 Phase III trials.

‍Diversity and inclusion is essential to promote health equity, and benefits scientific discovery. Judi for Eligibility, a powerful tool for evaluating and maintaining eligibility criteria in support of time-intensive cancer treatment, enables clinical teams to promote health equity, and is used on a significant number ofOncology trials—often bundled with Judi for DSMB, which provides globally compliant data collection and transport, role-based viewing restrictions for DMC and DSMB members, and a complete audit trail—to ensure trial safety; and Judi for Site andUser Qualification to streamline, qualify, and monitor remote eClinical training in real-time.

Integral for cancer research, Judi for Imaging is the industry leader for DICOM image management, secure upload, storage, and retrieval of clinical data, and is currently active in TK% of Oncology trials—often paired with Judi for Adjudication, the leading platform leveraged by CROs and sponsors onOncology trials, and best-in-class for endpoint adjudication workflow management. These solutions save enormous time and expense while maintaining trial integrity. See below to browse Judi by AG Mednet's Oncology-related case studies, articles, white papers, facts sheets, and more. AG Mednet's Judi platform is used within the entire clinical trial ecosystem—across all therapeutic areas.